Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Belief BioMed Reports Positive Data for Hemophilia Gene Therapy

publication date: May 20, 2022

Shanghai Belief Biomed reported positive results from an investigator-led clinical trial of its gene therapy for hemophilia B were published in The Lancet Haematology. In ten patients with moderate to severe hemophilia., there were no bleeding incidents during more than a year of follow-up after a one-time treatment with BBM-H901. The therapy was effective within 24 hours and did not cause significant side effects.  Belief Bio said the trial was the first intravenously injectable hemophilia B gene therapy product developed and tested in Asia. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital